{"id":"68ga-ga-pentixafor","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4301788","moleculeType":"Unknown","molecularWeight":"1706.62"},"_fixedAt":"2026-03-30T18:10:11.796120","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ga-PentixaFor binds to the CD47 protein on the surface of cancer cells, which can be recognized by the SIRPα receptor on the surface of macrophages. This interaction can inhibit the immune suppressive effects of CD47 and promote the phagocytosis of cancer cells by macrophages.","oneSentence":"Ga-PentixaFor is a radiopharmaceutical that targets the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:01.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Assessment of myocardial infarction and acute coronary syndrome"}]},"_fixedFields":["pubmed(23)"],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"recentPublications":[{"date":"2026 Mar 13","pmid":"41820762","title":"Optimal acquisition time of [(68)Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol.","journal":"EJNMMI research"},{"date":"2026 Mar 6","pmid":"41790412","title":"One-stop evaluation using [(68)Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT for visualization and localization of adrenal nodules in patients with primary aldosteronism.","journal":"Japanese journal of radiology"},{"date":"2026 Feb 28","pmid":"41760826","title":"[(68)Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma.","journal":"European journal of nuclear medicine and molecular imaging"},{"date":"2026 Feb 24","pmid":"41733766","title":"Machine learning-based model for prediction of KCNJ5 mutation in unilateral primary aldosteronism based on [(68)Ga]Ga-Pentixafor PET/CT.","journal":"EJNMMI research"},{"date":"2026 Apr","pmid":"41588208","title":"Evaluating chronic bone and soft tissue infections with [(68)Ga]Ga-Pentixafor PET/CT: a head-to-head comparison with scintigraphy.","journal":"European journal of nuclear medicine and molecular imaging"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CXCR4","[68Ga]Ga-PTF"],"phase":"phase_3","status":"active","brandName":"[68Ga]Ga-PentixaFor","genericName":"[68Ga]Ga-PentixaFor","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ga-PentixaFor is a radiopharmaceutical that targets the CD47/SIRPα axis. Used for Assessment of myocardial infarction and acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}